Epilepsy Clinical Trials

Epilepsy is a prevalent neurological disorder characterized by the enduring predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological, and social consequences of this condition.

Navigating the regulatory landscape is critical for the success of clinical trials in epilepsy. The US FDA sets stringent standards to ensure that new treatments are safe and effective. Understanding these regulatory requirements and implementing strategies to meet them are essential steps in the development and approval process of new epilepsy therapies. 

Approximately

1%

of people worldwide have epilepsy, making it one of the most common neurological conditions


About

30%

of individuals with epilepsy may not respond adequately to antiseizure medications, despite it being the primary 



The causes of epilepsy vary, including genetic factors, brain injuries, infections, and developmental disorders.


 

Our clinical team has over

120

years of combined clinical trial experience

 

Download Our Paper

Fill out this form to download our white paper on how to overcome the biggest obstacles in conducting an epilepsy clinical trial.

iNGENuCRO_Epilepsy

In light of the significant impact epilepsy has on individuals and society as a whole, continued research and awareness efforts are crucial to improve diagnosis, treatment, and ultimately, the quality of life for those living with this disease.

The development of clinical trial protocols that meet FDA approval standards is crucial for the success of new epilepsy treatments.